331 related articles for article (PubMed ID: 35971840)
1. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
Docherty KF; Welsh P; Verma S; De Boer RA; O'Meara E; Bengtsson O; Køber L; Kosiborod MN; Hammarstedt A; Langkilde AM; Lindholm D; Little DJ; Sjöstrand M; Martinez FA; Ponikowski P; Sabatine MS; Morrow DA; Schou M; Solomon SD; Sattar N; Jhund PS; McMurray JJV;
Circulation; 2022 Sep; 146(13):980-994. PubMed ID: 35971840
[TBL] [Abstract][Full Text] [Related]
2. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF.
Docherty KF; Jhund PS; Anand I; Bengtsson O; Böhm M; de Boer RA; DeMets DL; Desai AS; Drozdz J; Howlett J; Inzucchi SE; Johanson P; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Nicolau JC; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; McMurray JJV
Circulation; 2020 Oct; 142(17):1623-1632. PubMed ID: 32883108
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV
Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L
JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831
[TBL] [Abstract][Full Text] [Related]
6. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
Filippatos G; Ponikowski P; Farmakis D; Anker SD; Butler J; Fabien V; Kirwan BA; Macdougall IC; Metra M; Rosano G; Ruschitzka F; van der Meer P; Wächter S; Jankowska EA;
Circulation; 2023 May; 147(22):1640-1653. PubMed ID: 37051919
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
Martinez FA; Serenelli M; Nicolau JC; Petrie MC; Chiang CE; Tereshchenko S; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Ponikowski P; Sabatine MS; DeMets DL; Dutkiewicz-Piasecka M; Bengtsson O; Sjöstrand M; Langkilde AM; Jhund PS; McMurray JJV
Circulation; 2020 Jan; 141(2):100-111. PubMed ID: 31736328
[TBL] [Abstract][Full Text] [Related]
8. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
Berg DD; Docherty KF; Sattar N; Jarolim P; Welsh P; Jhund PS; Anand IS; Chopra V; de Boer RA; Kosiborod MN; Nicolau JC; O'Meara E; Schou M; Hammarstedt A; Langkilde AM; Lindholm D; Sjöstrand M; McMurray JJV; Sabatine MS; Morrow DA
Circulation; 2022 Jan; 145(3):158-169. PubMed ID: 34743554
[TBL] [Abstract][Full Text] [Related]
9. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Jackson AM; Dewan P; Anand IS; Bělohlávek J; Bengtsson O; de Boer RA; Böhm M; Boulton DW; Chopra VK; DeMets DL; Docherty KF; Dukát A; Greasley PJ; Howlett JG; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Ljungman CEA; Martinez FA; O'Meara E; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; Jhund PS; McMurray JJV
Circulation; 2020 Sep; 142(11):1040-1054. PubMed ID: 32673497
[TBL] [Abstract][Full Text] [Related]
11. Effect of dapagliflozin on anaemia in DAPA-HF.
Docherty KF; Curtain JP; Anand IS; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV;
Eur J Heart Fail; 2021 Apr; 23(4):617-628. PubMed ID: 33615642
[TBL] [Abstract][Full Text] [Related]
12. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV
JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447
[TBL] [Abstract][Full Text] [Related]
13. Markers of Iron Metabolism and Outcomes in Patients with Heart Failure: A Systematic Review.
Dhaliwal S; Kalogeropoulos AP
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982717
[TBL] [Abstract][Full Text] [Related]
14. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
Yeoh SE; Docherty KF; Campbell RT; Jhund PS; Hammarstedt A; Heerspink HJL; Jarolim P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Solomon SD; Sjöstrand M; Bengtsson O; Greasley PJ; Sattar N; Welsh P; Sabatine MS; Morrow DA; McMurray JJV
Circulation; 2023 May; 147(22):1670-1683. PubMed ID: 37039015
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.
Dewan P; Solomon SD; Jhund PS; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; DeMets DL; Sabatine MS; Bengtsson O; Sjöstrand M; Langkilde AM; Anand IS; Bělohlávek J; Chopra VK; Dukát A; Kitakaze M; Merkely B; O'Meara E; Schou M; Vinh PN; McMurray JJV;
Eur J Heart Fail; 2020 Jul; 22(7):1247-1258. PubMed ID: 32539224
[TBL] [Abstract][Full Text] [Related]
16. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
Docherty KF; Jhund PS; Claggett B; Ferreira JP; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
JAMA Cardiol; 2021 Nov; 6(11):1298-1305. PubMed ID: 34319398
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.
Docherty KF; Ogunniyi MO; Anand IS; Desai AS; Diez M; Howlett JG; Nicolau JC; O'Meara E; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Lindholm D; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Langkilde AM; Jhund PS; McMurray JJV
JACC Heart Fail; 2022 Jan; 10(1):52-64. PubMed ID: 34969498
[TBL] [Abstract][Full Text] [Related]
18. Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF.
Dewan P; Docherty KF; Bengtsson O; de Boer RA; Desai AS; Drozdz J; Hawkins NM; Inzucchi SE; Kitakaze M; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Verma S; Jhund PS; McMurray JJV
Eur J Heart Fail; 2021 Apr; 23(4):632-643. PubMed ID: 33368858
[TBL] [Abstract][Full Text] [Related]
19. Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?
Yeoh SE; Dewan P; Jhund PS; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Sjöstrand M; Langkilde AM; McMurray JJV;
Circ Heart Fail; 2020 Dec; 13(12):e007879. PubMed ID: 33164553
[TBL] [Abstract][Full Text] [Related]
20. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF.
Butt JH; Dewan P; DeFilippis EM; Biering-Sørensen T; Docherty KF; Jhund PS; Kosiborod MN; Martinez FA; Bengtsson O; Johansen ND; Langkilde AM; Sjöstrand M; Vaduganathan M; Solomon SD; Sabatine MS; Køber L; Fiuzat M; McMurray JJV
JACC Heart Fail; 2022 Aug; 10(8):543-555. PubMed ID: 35902157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
